Wednesday, July 8, 2026

biotech · Advanced Solid Tumors · Seasonal Allergic Rhinitis · PRME

Prime Medicine

Prime Medicine is a biotech organization headquartered in Cambridge, USA. It trades on NYSE under ticker PRME. Primary therapeutic focus areas include Advanced Solid Tumors, Seasonal Allergic Rhinitis, Artificial Intelli

60 First St, Cambridge, Massachusetts 02141, US HQ
2019 Founded
185 Employees
Public company Type
PRME · NYSE Ticker
Company details
Status
Public
HQ
60 First St, Cambridge, Massachusetts 02141, US
Founded
2019
Employees
185
Programs
17
Drugs
6
Patents
127
Clinical program

FPA008

Phase 2 · mab · Pigmented Villonodular Synovitis

FPA008 for Pigmented Villonodular Synovitis is a Phase 2 program (mab) at Prime Medicine with 1 ClinicalTrials.gov record(s).

← All Prime Medicine projects Phase 2 mab completed

Internal code FPA008-002

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Prime Medicine
Phase
Phase 2
Modality
mab
Indication
Pigmented Villonodular Synovitis
Status
completed
Trials
1

Clinical trials